An immunohistochemistry kit for detecting cancer

By developing monoclonal antibodies targeting human PD-L1 and related immunohistochemistry kits, the problem of insufficient detection accuracy and sensitivity of PD-L1 in the prior art has been solved, and high specificity and sensitivity to various cancers have been achieved. The test meets the needs of PD-1/PD-L1 target immunotherapy.

CN118777609BActive Publication Date: 2024-11-19ANHUI KECHENG INTELLIGENT HEALTH TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411273378.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-19
Estimated Expiration
2044-09-12

AI Technical Summary

Technical Problem

The lack of PD-L1 immunohistochemical antibodies with strong specificity and high sensitivity in the prior art, which is difficult to meet the needs of PD-1/PD-L1 target immunotherapy, especially in cancer detection and diagnosis. The problem.

Method used

A monoclonal antibody targeting human PD-L1, containing specific heavy and light chain variable region amino acid sequences, combined with HRP-tagged goat anti-mouse IgG, was developed for immunohistochemistry kits, equipped with DAB display Toner and hematoxylin counterstaining agents are used to detect cancers associated with PD-L1.

Benefits of technology

High specificity and sensitivity detection of PD-L1 expression can be realized, and it can effectively identify various cancers such as non-small cell lung cancer and squamous cell carcinoma. The results are consistent with the detection results of commercial antibodies, showing good specificity and reliability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118777609B_ABST
    Figure CN118777609B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of disease diagnosis, and specifically relates to an immunohistochemical kit for detecting cancer. The immunohistochemical kit comprises a primary antibody reagent and a secondary antibody reagent, wherein the primary antibody reagent is a monoclonal antibody targeting human PD-L1, and the monoclonal antibody targeting human PD-L1 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 1, 2 and 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 6, 7 and 8, respectively. The present invention has confirmed that the cancer detection immunohistochemical kit prepared by using a homemade anti-PD-L1 antibody can specifically and sensitively detect the expression of PD-L1 in cancer tissues, and its detection effect is equivalent to that of the existing commercial anti-PD-L1 antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of disease diagnosis, and in particular relates to an immunohistochemistry kit for detecting cancer. Background Art

[0002] PD-L1 (programmed death ligand 1) is programmed death receptor ligand 1, and is the ligand of PD-1 (programmed cell death 1). PD-1 is a transmembrane protein on the cell membrane, expressed on immune cells such as T cells and B cells, as well as tumor cells. Studies have shown that when PD-L1 on the tumor cell membrane binds to PD-1 on immune cells such as T cells, it inhibits the activation, differentiation and proliferation of T cells, allowing tumor cells to evade T cell killing and achieve immune escape.

[0003] Immunohistochemistry (IHC) detection is an effective method to evaluate the expression status of PD-L1 in tumor tissue and is widely used in the detection and diagnosis of various malignant tumors including gastric cancer.

[0004] The art discloses some anti-PD-L1 immunohistochemistry antibodies for detecting and diagnosing cancer. For example, Patent Document 1 (CN109963872B, published on April 11, 2023) discloses diagnostic anti-PD-L1 antibodies and their uses, wherein the anti-PD-L1 antibodies bind to epitopes within human PD-L1 with high specificity and repeatability, and can be used to assess PD-L1 expression in tissue samples to assist in patient stratification. Patent Document 2 (CN106604933B, published on August 10, 2021) discloses anti-PD-L1 antibodies and their diagnostic uses, wherein the antibodies are used to manufacture reagents or kits for use in a method for detecting the presence or expression level of PD-L1 in a biological sample from a subject.

[0005] Although there are several commonly used PD-L1 immunohistochemical detection antibodies on the market, given the wide application of PD-1 / PD-L1 target immunotherapy and the huge potential market demand, other PD-L1 immunohistochemical antibodies with strong specificity and high sensitivity are urgently needed in this field. Summary of the invention

[0006] In order to solve the above problems, the present invention provides an immunohistochemistry kit for detecting cancer, wherein the immunohistochemistry reagent of the immunohistochemistry kit comprises a primary antibody reagent and a secondary antibody reagent, wherein the primary antibody reagent is a monoclonal antibody targeting human PD-L1, and the monoclonal antibody targeting human PD-L1 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 1, 2 and 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 6, 7 and 8, respectively.

[0007] Furthermore, the monoclonal antibody targeting human PD-L1 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 1, 2 and 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 6, 7 and 8, respectively.

[0008] Furthermore, the heavy chain variable region has an amino acid sequence as shown in SEQ ID NO:4, and the light chain variable region has an amino acid sequence as shown in SEQ ID NO:9.

[0009] Furthermore, the monoclonal antibody targeting human PD-L1 comprises a heavy chain as shown in SEQ ID NO: 5 and a light chain as shown in SEQ ID NO: 10.

[0010] Furthermore, the secondary antibody is HRP-labeled goat anti-mouse IgG.

[0011] Furthermore, the immunohistochemistry kit also contains a developer and a counterstain.

[0012] Furthermore, the color developer is DAB color developer, and the counterstain is hematoxylin counterstain.

[0013] Furthermore, the immunohistochemistry kit may optionally include an antigen retrieval solution, a blocking agent and / or a blocking agent well known to those skilled in the art.

[0014] Further, the cancer can be any cancer associated with PD-L1 overexpression, which can be selected from, for example, non-small cell lung cancer, squamous cell carcinoma, small cell lung cancer, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, leukemia, head and neck cancer, etc.

[0015] The present invention also provides a monoclonal antibody targeting human PD-L1, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 1, 2 and 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 6, 7 and 8, respectively.

[0016] Furthermore, the monoclonal antibody targeting human PD-L1 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 1, 2 and 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 6, 7 and 8, respectively.

[0017] Furthermore, the heavy chain variable region has an amino acid sequence as shown in SEQ ID NO:4, and the light chain variable region has an amino acid sequence as shown in SEQ ID NO:9.

[0018] Furthermore, the monoclonal antibody targeting human PD-L1 comprises a heavy chain as shown in SEQ ID NO: 5 and a light chain as shown in SEQ ID NO: 10.

[0019] In another aspect, the present invention also provides a nucleotide encoding a monoclonal antibody targeting human PD-L1 as described herein.

[0020] In another aspect, the present invention provides an expression vector comprising a nucleic acid molecule as described herein.

[0021] In another aspect, the present invention provides a host cell comprising the expression vector as described herein.

[0022] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, and include but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phage or M13 phage and animal viruses, etc. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40). A vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication initiation site. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The ELISA test results of the monoclonal antibody targeting PD-L1 screened in Example 1 are shown.

[0024] Figure 2 The results of immunohistochemical detection of clinical gastric cancer pathological sections using the monoclonal antibody targeting PD-L1 screened in Example 1 are shown.

[0025] in Figure 2 Part A in the figure is the hematoxylin-eosin staining control. Figure 2 Part B in the figure shows the immunohistochemical staining results of anti-PD-L1 monoclonal antibody. Figure 2 Part C shows the immunohistochemical staining results of a commercial anti-PD-L1 monoclonal antibody (22C3). DETAILED DESCRIPTION

[0026] The present invention is further described below with reference to specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0027] Example 1: Preparation of anti-human PD-L1 monoclonal antibody

[0028] Preparation of PD-L1 monoclonal antibody and construction of lentiviral plasmid Lenti-CMV-PD-L1-T2A-GFP:

[0029] The constructed plasmid and packaging plasmids pDD and pVSVg were transfected into 293T cells using PEI at a ratio of 1:1:0.5. After culturing for 36 hours, the supernatant was collected, centrifuged and the virus was concentrated. After the titer was determined, 293T cells were infected, and cells stably expressing the antigen PD-L1 were successfully obtained after puromycin selection.

[0030] Experimental steps:

[0031] 1.1 Primers were designed using the Gibson ligation system to amplify the human PD-L1 sequence and GFP sequence, respectively, and the PCR products were recovered by gel.

[0032] 1.2 Digest Lenti-CMV-Puro plasmid with BamHI and recover the digestion product from gel.

[0033] 1.3 Use the Gibson ligation system to connect, transform, extract plasmids, sequence and express and verify.

[0034] 1.4 The correctly identified plasmid was named Lenti-CMV-PD-L1-T2A-GFP plasmid.

[0035] Construction of 293T cell line stably expressing PD-L1: 293T-PD-L1:

[0036] Experimental Materials

[0037] Lentiviral vector plasmid Lenti-CMV-PD-L1-T2A-GFP; packaging plasmids: pDD, pVsVG; 293T cells; 0.25% trypsin; DMEM; FBS; Opti-MEM; lip2000; BSA.

[0038] Experimental procedures

[0039] 1) 293T cell inoculation: 293T cells with good growth status were digested with 0.25% trypsin and the cell concentration was adjusted to 6×10 5 / mL, take 10mL and inoculate it in a 10cm culture dish, culture it at 37℃, 5% carbon dioxide for 18 hours, so that the cell fusion degree reaches 60%-70%, and replace the culture medium with Opti-MEM half an hour before transfection.

[0040] 2) Virus packaging: Add 7ug Lenti-CMV-PD-L1-T2A-GFP plasmid, 5ug pDD and 3.5ug pVsVg to 500uL OPTI-MEM and mix well; take 30uL lip2000 and add it to 500uL OPTI-MEM and mix well, let it stand at room temperature for 5 minutes, slowly add it to the plasmid mixture and mix well, let it stand at room temperature for 15 minutes, add it drop by drop to the culture dish and mix well. After 6 hours, replace it with fresh DMEM culture medium containing 10% FBS 1% BSA.

[0041] 3) Virus concentration: After 60 hours of culture, collect the supernatant, centrifuge at 3000rpm at 4℃ for 10 minutes, filter through a 0.45um filter membrane, ultracentrifuge at 25000rpm at 4℃ for 2 hours, discard the supernatant, resuspend the precipitate with 300uL of DMEM culture medium containing 10% FBS 1% BSA, incubate at 4℃ overnight, divide into 50uL / tube, freeze with dry ice and store at -80℃.

[0042] 4) 293T cells were infected with lentivirus to construct a 293T cell line stably expressing PD-L1, named 293T-PD-L1.

[0043] The prepared 293T-PD-L1 cells were used to prepare monoclonal antibodies targeting PD-L1.

[0044] Cell immunization with 293T-PD-L1 cells: Four 6-8 week old SPF grade Balb / c female mice were selected, blood was collected from their orbits one day before immunization, and serum was separated and used as a negative control. 7 293T cells stably expressing PD-L1 were injected into mice subcutaneously at multiple points. On days 10 and 20, 5×106 293T cells stably expressing PD-L1 were used for the second and third immunizations, respectively. On day 25, blood was collected from the mouse orbits, and the PD-L1 antibody titer was detected by ELISA. The mice with the highest antibody titer were selected and injected with 2×10 6 On the 30th day, spleen cells of immune mice were prepared, and positive B cells that could produce PD-L1 antibodies were sorted by flow cytometry (FCM). The VH and VL sequences were obtained and verified by single-cell RT-PCR technology, and finally a high-affinity monoclonal antibody against PD-L1 (including the heavy chain shown in SEQ ID NO: 5 and the light chain shown in SEQ ID NO: 10) was screened out.

[0045] Example 2: ELISA detection of the binding between monoclonal antibodies targeting PD-L1 and PD-L1 recombinant protein

[0046] (1) Antigen coating: dilute the antigen (PD-L1 recombinant protein expressed and purified from the 293T-PD-L1 cell line prepared in Example 1) to 10 µg / mL with 1× carbonate coating buffer (Na2CO3 (1.59 g) + NaHCO3 (2.93 g), adjust the pH value to 50 mL), take 50 µL of the diluted antigen and coat a 96-well plate at 0.5 µg / 200 µL (set up a positive control group, a negative control group and an experimental group, with 3 replicates for each group);

[0047] (2) Blocking: Aspirate the liquid in the wells, wash three times with washing buffer (1× PBS plus Tween-20 to make a 0.05% solution), add 100 μL of blocking solution (skim milk powder (1 g) + 1× TBST (20 mL)) to each well, and incubate at 37°C for 1 h;

[0048] (3) Incubation with the test antibody: The 96-well plate was placed in a plate washer and washed five times. Different concentrations of the test antibody were added according to the different groups. The plate was placed at 37°C for 1 hour. The liquid in the wells was discarded and the plate was washed on a shaker with washing buffer for 3 minutes. The washing was repeated three times.

[0049] (6) Enzyme-labeled secondary antibody incubation: Add 100 μL of diluted enzyme-labeled secondary antibody (1:5000 dilution) to each well of the 96-well plate and incubate at 37°C in the dark for 30 min.

[0050] (7) Color development: Wash the 96-well plate in a plate washer 6-7 times, add 100 TMB color development solution to each well. The liquid in the well turns blue and develops at 37°C in the dark for 5-15 min.

[0051] (8) Detect absorbance: Add 50 μL of stop solution to each well (the liquid in the well turns yellow) and detect absorbance at 450 nm using an ELISA reader.

[0052] The results are as follows Figure 1 As shown, the results show that the binding activity of the monoclonal antibody targeting PD-L1 screened in Example 1 to the PD-L1 protein is basically equivalent to that of the commercial anti-PD-L1 monoclonal antibody (22C3). ELISA was also used to test whether the antibody can recognize other antigens. The results showed that the monoclonal antibody targeting PD-L1 cannot recognize other antigens and has good specificity.

[0053] Example 3: Immunohistochemical validation of monoclonal antibodies targeting PD-L1

[0054] Take clinical gastric cancer pathological sections and perform the following operations:

[0055] (1) Dewaxing, hydration and antigen retrieval of tissue sections. The sections were placed in xylene and soaked for 15 min × 2 times. After shaking off the excess liquid, the sections were placed in anhydrous ethanol and soaked for 30 s. After shaking off the excess liquid, the sections were placed in 95% ethanol and soaked for 30 s. After shaking off the excess liquid, the sections were placed in 70% ethanol and soaked for 30 s. After rinsing in running water for 3 min, the sections were rinsed in PBS solution (0.01 mol / L, pH 7.2-7.4) for 3 min × 2 times. The sections were placed in a steam autoclave at 121°C for heat-induced antigen retrieval with antigen retrieval solution (pH 9, Histofne; Nichirei Biosciences, Tokyo, Japan) for 15 min and cooled naturally to room temperature. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide. The sections were rinsed in PBS solution for 3 min × 3 times.

[0056] (2) Blocking: Add 50 μL of goat serum to the slices and incubate at 37°C for 30 min. Remove excess liquid and do not wash.

[0057] (3) Incubation with primary antibody. The slides were then incubated with the anti-human PD-L1 monoclonal antibody (1 μg / ml) obtained in Example 1 at 4°C overnight. The slides were then rinsed with PBS solution for 3 min × 3 times.

[0058] (4) Incubate with fluorescent secondary antibody. Add 50 μL of antibody dilution containing HRP-labeled goat anti-mouse IgG to the tissue sections, incubate at 37°C in the dark for 30 min, and rinse with PBS solution for 3 min × 3 times.

[0059] (5) Color development. Add 50 μL of DAB color development solution to the tissue section and incubate at room temperature for 3-10 minutes.

[0060] (6) Counterstaining: Counterstain the tissue sections with hematoxylin for 1-2 minutes and then bluing with hydrochloric acid alcohol for 1 minute.

[0061] (7) Dehydrate, make transparent, seal the slides with resin mounting medium, and observe under a microscope.

[0062] The results are as follows Figure 2 As shown in Part B, Figure 2 Part A in the figure is a tissue section stained with hematoxylin-eosin using a standard procedure. It can be seen that the clinical gastric cancer pathological section was positive after detection of the monoclonal antibody targeting PD-L1 of the present invention, which is consistent with the immunohistochemical detection result of the commercial anti-PD-L1 monoclonal antibody (22C3) ( Figure 2 in Section C).

[0063] It should be noted that the preferred embodiments of the present invention are given in the specification of the present invention, but the present invention can be implemented in many different forms and is not limited to the embodiments described in this specification. These embodiments are not intended to be additional limitations on the content of the present invention. The purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive. In addition, the above-mentioned technical features continue to be combined with each other to form various embodiments not listed above, which are all considered to be within the scope of the present invention specification; further, for ordinary technicians in this field, they can be improved or transformed according to the above description, and all these improvements and transformations should belong to the protection scope of the claims attached to the present invention.

Claims

1. An immunohistochemistry kit for detecting cancer, characterized in that: The immunohistochemistry reagents of the immunohistochemistry kit comprise a primary antibody reagent and a secondary antibody reagent, wherein the primary antibody reagent is a monoclonal antibody targeting human PD-L1, and the monoclonal antibody targeting human PD-L1 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 1, 2 and 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 6, 7 and 8, respectively.

2. The immunohistochemistry kit according to claim 1, characterized in that The heavy chain variable region has the amino acid sequence shown in SEQ ID NO:4, and the light chain variable region has the amino acid sequence shown in SEQ ID NO:

9.

3. The immunohistochemistry kit according to claim 1, characterized in that The monoclonal antibody targeting human PD-L1 comprises a heavy chain as shown in SEQ ID NO: 5 and a light chain as shown in SEQ ID NO:

10.

4. The immunohistochemistry kit according to claim 1, characterized in that The secondary antibody is HRP-labeled goat anti-mouse IgG.

5. The immunohistochemistry kit according to claim 1, characterized in that The immunohistochemistry kit also comprises a developer and a counterstain.

6. The immunohistochemistry kit according to claim 5, characterized in that The color developer is DAB color developer, and the counterstain is hematoxylin counterstain.

7. The immunohistochemistry kit according to claim 1, characterized in that: The immunohistochemistry kit may further optionally contain an antigen retrieval solution, a blocking agent and / or a blocking agent.

8. A monoclonal antibody targeting human PD-L1, characterized in that: The monoclonal antibody targeting human PD-L1 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 1, 2 and 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 6, 7 and 8, respectively.

9. A nucleotide encoding the monoclonal antibody targeting human PD-L1 according to claim 8.